港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理授权合作显著带动业绩增长

智通财经2025-06-16

智通财经APP获悉，和誉-B(02256)盘中涨超9%，截至发稿，涨7.03%，报10.96港元，成交额4488.85万港元。消息面上，6月10日，和誉医药宣布，中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请，将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外，公司近日宣布，附属和誉医药已收到默克根据授权协议支付的匹米替尼(ABSK021)全球商业化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2543490096?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-16 11:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543490096","market":"hk","top_or_hot":-1,"title":"港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，和誉-B(02256)盘中涨超9%，截至发稿，涨7.03%，报10.96港元，成交额4488.85万港元。消息面上，6月10日，和誉医药宣布，中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请，将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外，公司近日宣布，附属和誉医药已收到默克根据授权协议支付的匹米替尼(ABSK021)全球商业化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1305544.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-16 11:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1305544.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，和誉-B(02256)盘中涨超9%，截至发稿，涨7.03%，报10.96港元，成交额4488.85万港元。消息面上，6月10日，和誉医药宣布，中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请，将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外，公司近日宣布，附属和誉医药已收到默克根据授权协议支付的匹米替尼(ABSK021)全球商业化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1305544.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1305544.html","article_id":"2543490096","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543490096","pubTimestamp":1750045062,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，6月10日，和誉医药宣布，中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请，将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外，公司近日宣布，附属和誉医药已收到默克根据授权协议支付的匹米替尼全球商业化选择权行权费8500万美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","02256":"和誉-B"},"translate_title":"Hong Kong stock changes Heyu-B (02256) rose more than 9% intraday, pimetinib listing application was accepted, authorization cooperation significantly drove performance growth","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":1},"content_text":"智通财经APP获悉，和誉-B(02256)盘中涨超9%，截至发稿，涨7.03%，报10.96港元，成交额4488.85万港元。消息面上，6月10日，和誉医药宣布，中国国家药品监督管理局已受理其自主研发的CSF-1R高选择性小分子抑制剂匹米替尼的新药上市申请，将其作为治疗成人腱鞘巨细胞瘤患者的1类创新药。此外，公司近日宣布，附属和誉医药已收到默克根据授权协议支付的匹米替尼(ABSK021)全球商业化选择权行权费8500万美元。该选择权行权费将确认为2025年度公司实现的营收。平安证券指出，凭借着强大的研发实力和丰富的管理运营经验，和誉先后与礼来、默克、艾力斯等国内外知名药企达成合作。2024年公司首次实现全年盈利，净利润达2830万元，全年收入达5.04亿元，主要来自于授权合作收入，包括与默克就CSF-1R抑制剂匹米替尼达成合作确认的7000万美元首付款，以及与艾力斯就下一代EGFRTKI达成合作收取的里程碑付款100万美元。公司现金流管理稳健，截至2024年底现金及银行结余达19.59亿元，在手现金储备充沛。2025年公司启动不超过2亿港元新一轮的股票回购计划，进一步提升股东价值，同时再次彰显出管理团队对公司未来发展前景的坚定信心。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2543490096","isCrawlerRequest":true}

港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理 授权合作显著带动业绩增长

精彩评论

港股异动 | 和誉-B(02256)盘中涨超9% 匹米替尼上市申请获受理授权合作显著带动业绩增长